-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics Q2 FY26 net loss narrows to $6.38 million; operating loss improves 11.57% to $6.08 million

PUBT·08/14/2026 10:35:20
Listen to the news
Rein Therapeutics Q2 FY26 net loss narrows to $6.38 million; operating loss improves 11.57% to $6.08 million
  • Rein Therapeutics posted a net loss of USD 6.38 million for the quarter ended June 30, 2026, narrowing from USD 6.82 million.
  • Operating loss narrowed to USD 6.08 million from USD 6.87 million as total operating expenses fell to USD 6.08 million.
  • Research and development expense dropped to USD 3.64 million from USD 4.29 million, due to timing of third-party CRO services.
  • Other expense swung to USD 299,000 from income of USD 49,000, driven by discount amortization on promissory notes.
  • Cash, cash equivalents and investments totaled USD 43.6 million at June 30, 2026; runway expected into Q1 2028, with interim Phase 2 RENEW data targeted in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-350270), on August 14, 2026, and is solely responsible for the information contained therein.